Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (303)	3/23/1998 9:52:00 AM
From: Ian@SI	Respond to of 1321

John, There's a couple other threads in the Biotech area about companies researching Photodynamic drugs. I picked QLT because it was most advanced: It has approved treatments generating revenues; It is about 1 year into Phase III for AMD treatment. Ian.

To: John O'Neill who wrote (303)	3/23/1998 1:12:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1321

John, There are two competitors in the PDT business that have SI threads: Miravant, and Pharmacyclics (PCYC). They are both at an earlier stage than QLTIF. I personally hold only PCYC (which is at the earliest stage of the three), but primarily because of its radiation sensitizer (a bigger market) rather than its light sensitizer. However its light sensitizer (LuTex) appears to have a number of advantages over QLTIF's current drug - mainly it already works in the 730nm region and seems to cause much less photosensitivity reactions than QLTIF's drug. Peter